Metformin

ID: metformin

Aliases: metformin hydrochloride, biguanide

Type: compound

Route/form: oral prescription tablet or extended-release tablet

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: human_physiology, human_rct, human_rct_negative, label, meta_analysis, review

Linked sources: 8

Broad outcomes: Fat loss / metabolic health, Longevity / mitochondrial / redox, Muscle growth / performance / recovery, mTORC / autophagy / nutrient signaling

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• hepatic glucose production reduction
• mitochondrial complex I / redox-energy stress signaling
• AMPK and AMPK-independent nutrient sensing
• mTORC1-adjacent exercise adaptation effects

Optimization domains

• metabolic
• type 2 diabetes
• insulin resistance
• AMPK
• mTORC
• exercise adaptation
• longevity discussion

Research basis

• Label and Diabetes Prevention Program data make metformin a core human metabolic-health reference compound rather than a fringe supplement.
• Mechanistically it belongs in the mTORC map because energy-stress/AMPK/lysosomal signaling can intersect with mTORC1 and nutrient-sensing biology.
• It is a useful comparator for berberine because both get discussed through AMPK/metabolic-sensor language, but metformin has much stronger medical-use evidence.

Limits, risks, and missing evidence

• Human exercise studies are mixed, but the MASTERS trial and later physiology work support a real caution that metformin can blunt some resistance-training or mitochondrial adaptations in certain older-adult contexts.
• Longevity claims remain indirect; approved use is glycemic control in type 2 diabetes, not healthy-user life extension.
• Renal function, lactic-acidosis warnings, B12 depletion, GI intolerance, and interactions with other glucose-lowering drugs matter.

Risk flags

• prescription
• renal function context
• lactic acidosis warning
• B12 depletion
• GI tolerability
• exercise adaptation tradeoff
• medical supervision

Linked papers, labels, and reviews

1. DailyMed label: METFORMIN HYDROCHLORIDE tablet, film coated
   label / dailymed_metformin_label
   Official metformin label context: oral biguanide for type 2 diabetes, glycemic-control indication, dosing, contraindications, and lactic-acidosis/B12/renal precautions.
2. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
   human_rct / pubmed_metformin_dpp_2002
   Diabetes Prevention Program RCT; key human prevention/metabolic anchor for metformin versus lifestyle intervention.
3. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial
   human_rct_negative / pubmed_metformin_masters_hypertrophy_2019
   MASTERS trial; central caution for performance users because metformin blunted resistance-training hypertrophy in older adults and trended against mTORC1 signaling.
4. Skeletal muscle adaptations to exercise are not influenced by metformin treatment in humans: secondary analyses of 2 randomized, clinical trials
   human_rct / pubmed_metformin_exercise_secondary_2022
   Counterpoint human analysis finding skeletal-muscle exercise adaptations were not influenced by metformin in two randomized trials; keeps the exercise-blunting claim nuanced.
5. Metformin suppresses the mitochondrial and transcriptional response to exercise, revealing a conserved BCL6B-associated angiogenic program
   human_physiology / pubmed_metformin_exercise_mito_transcriptome_2025
   Human/mouse mechanistic exercise-adaptation source; supports caution that metformin can alter mitochondrial and transcriptional responses to aerobic training.
6. Cellular and Molecular Mechanisms of Metformin Action
   review / pmc_metformin_cellular_mechanisms_2021
   Mechanistic review of metformin, mitochondrial complex I, AMPK-dependent and independent mechanisms, lysosomal signaling, and nutrient-sensing pathways.
7. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis
   meta_analysis / pubmed_metformin_antipsychotic_weight_meta_2016
   Double-blind placebo-controlled trial meta-analysis for metformin in antipsychotic-associated weight gain; useful non-diabetes body-weight context.
8. Effects of exercise, metformin and their combination on glucose metabolism in individuals with abnormal glycaemic control: a systematic review and network meta-analysis
   meta_analysis / pubmed_metformin_exercise_glucose_network_meta_2024
   Network meta-analysis comparing exercise, metformin, and combination treatment in prediabetes/T2D; useful for positioning metformin against lifestyle/exercise effects.